Expediting Research

GlaxoSmithKline (GSK) and the University of North Carolina at Chapel-Hill (UNC) will launch a jointly owned novel HIV Cure Center, as well as a...

Vpu Inhibitor Candidate

BIT225 is a new type of antiviral called a Vpu inhibitor, which researchers are investigating to treat both HIV and HIV/hepatitis C (HCV) co-infection....

Countdown to a Cure

by Jeannie Wraight As part of the Countdown to a Cure Initiative, amfAR (The Foundation for AIDS Research) will direct $20 million, of a $100...

Women & PrEP

LifeGuide It's a Man's World Research on women & PrEP needs to keep pace by Jeannie Wraight   Whereas HIV cure and HIV prevention are two very different...

The True End of AIDS

LifeGuide Trump Card Treatment and prevention are important, but an HIV cure will be the true end of AIDS by Jeannie Wraight Lately, we have been hearing a...
A&U America's AIDS Magazine

Cure—Or Bust

LifeGuide Cure—or Bust Amid advances and setbacks in care, we must still aim for the end of HIV by Jeannie Wraight   I recently read a rather angry reader...

Good News, Bad News

LifeGuide Good News, Bad News The HIV cure front faces disappointment mixed with hope by Jeannie Wraight The past year has been a difficult one in the HIV...

Checking the Map

LifeGuide Destination: Cure Checking the Map Where are we on the road to a cure? by Jeannie Wraight The past year has been wrought with disappointment on the HIV...

Cure News

News of the Day The latest reports on HIV cure research show momentum by Jeannie Wraight Here’s a look at some of the HIV cure headlines over...

David Evans

Risk & Reward Activist David Evans weighs in on next steps in cure advocacy & research by Jeannie Wraight In the late 1980s and throughout the ’90s,...

LATEST POSTS

HIV & Isolation: Who Me?

Here I am, back in my hometown for eight years now. I don’t regret the move, per se, but it has presented me with...

Richard Renaldi: Gallery